Project Grant HT94252410036
Award Date
12/15/23
Completion Date
12/14/26
Dollars Obligated
$995K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This federal Project Grant award of $1,146,270.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Wisconsin System. The grant supports research targeting a lipid kinase regulator of nuclear AKT in breast cancer, with a performance period from July 15, 2023 to July 14, 2026. The University of Wisconsin System, through its University of Wisconsin - Madison division, will conduct this biomedical research to...
The University of Wisconsin System has been awarded a $516,366 federal Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program. The grant, with a performance period from September 1, 2024 to August 31, 2027, will fund research to target immunotherapy-resistant lesions and eradicate oligometastatic prostate cancer. This research initiative aims to transform healthcare for military service members and the broader...
This $1,146,270 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Wisconsin System to target a lipid kinase regulator of nuclear Akt in breast cancer. The project aims to transform health care for Service Members and the American public through innovative and impactful research, with a focus on medical solutions for the battlefield. The grant will fund research activities at the University of...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, provides $155,500.00 to the University of Wisconsin System to develop a model for studying tumor-normal cell interaction in vitro for high-throughput drug screening. The award period runs from December 1, 2024 to November 30, 2025. The project aims to advance medical research and treatment of conditions relevant to military personnel and the broader...
The University of Wisconsin-Madison will receive $1,377,598 under a three-year Project Grant from the Defense Health Agency to investigate medical solutions for targeting dysregulated histone-modifying enzymes driving prostate cancer cell survival after androgen deprivation therapy. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative solutions for battlefield...
This federal Project Grant award, valued at $1,555,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the University of Wisconsin System's research initiative to develop population modeling to optimize equitable ovarian cancer outcomes. The project aims to transform healthcare for military service members and the broader public by advancing innovative research on disease prevention, diagnosis, and...
The Defense Health Agency has awarded a $862,751 Project Grant to the University of Wisconsin-Milwaukee (UWM) under the Military Medical Research and Development program (CFDA 12.420). The grant, effective June 1, 2024 through May 31, 2027, will fund a research project to study the "Impact of Recent Childbirth on Breast Cancer Prognosis and Tumor Molecular Phenotypes Among Young Black and White Women." This grant supports UWM's ongoing biomedical research initiatives focused on...
The University of Wisconsin-Madison will receive $1,145,080 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program. The grant will fund research from February 2021 to January 2024 to therapeutically target a lipid kinase regulator of mutant p53 in breast cancer. Through this award provided by the CFDA 12.420 program, the University of Wisconsin-Madison aims to investigate medical solutions for the battlefield and...
The University of Wisconsin-Madison will receive $1.17 million over four years through a Project Grant from the Defense Health Agency under the Military Medical Research and Development program. The grant will fund research to interrogate the intersection of prostate-specific membrane antigen and PI3K pathway signaling as a novel treatment approach for treatment-resistant prostate cancer. The University will investigate medical solutions for prostate cancer with the goals of transforming patient...
This $785,833 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports advanced research to target immunotherapy-resistant lesions and eradicate oligometastatic prostate cancer. Awarded to the University of Wisconsin System, the research aims to transform healthcare for military service members and the broader public by investigating innovative approaches to disease prevention, diagnosis,...